While empagliflozin may not be suitable for everyone, it represents a significant advancement in diabetes management, offering a promising option for many people living with this chronic condition
The clinical read-throughs are accumulating: a randomized trial (Hendershot et al., JAMA Psychiatry 2025) showed semaglutide cut drinks per drinking day, heavy drinking days, and cravings (and even cigarettes) versus placebo
Some hunger is normal and healthy, and learning to manage it with food strategies strengthens long-term success after eventually discontinuing the medication
Low Wang CC, Hess CN, Hiatt WR, Goldfine AB
Guarnera G, DeRosa A, Camerini R
GLP-1 drugs like Ozempic and Mounjaro have helped many people lose weight and manage type 2 diabetes, but a big question remains: what happens when people stop using them